The European Committee for Treatment and Research in MS (ECTRIMS) annual meeting presented new data that helped to clarify the mode of action of anti-CD20 agents and address some safety issues that have arisen during the COVID-19 pandemic. Read More
Latest News
CLINICAL CASES IN MS – CASE 1: Neurological symptoms after COVID-19 vaccination
November 2, 2021Watch Dr. Daniel Selchen as he shares his thoughts about this case.
Linda H., 48, is a partner at an accountancy firm, married with no children. She presents with paresthesiae following vaccination for COVID-19. She has no history of medical or neurological conditions and no pertinent family history. Read More
ECTRIMS 2021 SLIDE DECK
October 22, 2021Selected highlights from ECTRIMS 2021
Virtual Congress – 13-15 October 2021
52 slides
Scientific review:
Dr. Daniel Selchen, Senior Consultant, BARLO MS centre, St. Michael’s Hospital, Toronto, Canada
Read More
How prognostic is NEDA?
October 20, 2021A new study has found that a high proportion of MS patients with no evidence of disease activity (NEDA) in the first two years of treatment will experience relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA) (Prosperini et al. Neurol Neuroimmunol Neuroinflamm 2021;8:e1059). Read More